The main reasons for using SGLT2i or GLP-1 RA in the patients who were preferably prescribed these agents were obesity (BMI ≥ 27 kg/m2 and T2DM) at 85.6%, uncontrolled DM indicated by using two or more other antidiabetic agents (68.5%), the presence of high risk for ASCVD (23.9%), and established ASCVD (14%), as presented in Table 4. The gene discussed is GLP1R; the disease is Obesity.